Advertisement

Advertisement

DMPHF Stock Latest News

Dermapharm Rated Hold as Growth Normalizes and Risks Temper Upside; Price Target Reiterated at $44

RatingsDermapharm Rated Hold as Growth Normalizes and Risks Temper Upside; Price Target Reiterated at $44

Dermapharm: Improving Margins but Modest Growth Outlook Leads Piasta to Reiterate Hold and Maintain $44 Price Target

PremiumRatings

Dermapharm: Improving Margins but Modest Growth Outlook Leads Piasta to Reiterate Hold and Maintain $44 Price Target

1M ago

Dermapharm: Hold Rating Reiterated as Execution Risks Temper Growth Outlook; Price Target Maintained at $44

PremiumRatings

Dermapharm: Hold Rating Reiterated as Execution Risks Temper Growth Outlook; Price Target Maintained at $44

1M ago

Hold Rating Maintained as Results Track Guidance; €44 Price Target Kept Unchanged

PremiumRatings

Hold Rating Maintained as Results Track Guidance; €44 Price Target Kept Unchanged

2M ago

Is DMP a Buy, Before Earnings?

PremiumPre-Earnings

Is DMP a Buy, Before Earnings?

5M ago

Fabian Piasta Reiterates Hold Rating and Keeps $34 Price Target as Improved Profitability Aligns With Expectations

PremiumRatingsFabian Piasta Reiterates Hold Rating and Keeps $34 Price Target as Improved Profitability Aligns With Expectations

5M ago

Dermapharm: Muted Growth Outlook and Arkopharma Uncertainty Underpin Hold Rating

Ratings

Dermapharm: Muted Growth Outlook and Arkopharma Uncertainty Underpin Hold Rating

6M ago

Hold Rating Maintained on Dermapharm as Profitability Gains Offset by Weak Top-Line Momentum and Limited Near-Term Upside

Ratings

Hold Rating Maintained on Dermapharm as Profitability Gains Offset by Weak Top-Line Momentum and Limited Near-Term Upside

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >